Previous 10 | Next 10 |
- 60% response rate observed among 10 evaluable patients - F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observed - Conference call on Tuesday,...
MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024, 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation : June 3, 2024, 1:30-4:30 p.m. CT UTRECHT, The Netherlands and CAMB...
2024-05-22 17:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-13 12:47:21 ET More on Merus Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement FDA accepts Merus application for Zeno for lung, pancreatic cancer Gilead to invest in Merus as part of a research deal Seeking Alpha’s Quant ...
Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics &...
2024-05-09 12:45:05 ET More on Merus Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement FDA accepts Merus application for Zeno for lung, pancreatic cancer Gilead to invest in Merus as part of a research deal Seeking Alpha’s Quant ...
Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDAC Based on the Companyȁ...
2024-05-06 16:45:41 ET More on Merus Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement Gilead to invest in Merus as part of a research deal Seeking Alpha’s Quant Rating on Merus Historical earnings data for Merus Financia...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today an...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
News, Short Squeeze, Breakout and More Instantly...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...
2024-07-13 04:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), tod...